AHR and asthma: Although the primary endpoint, a change from baseline in MCh PC20 FEV1 at 24 h, was not met in this exploratory early phase asthma clinical trial, a single‐IV dose of N6022 5 mg demonstrated a clinically significant reduction in AHR compared with placebo over 7 days.